N-alpha-L-rhamnopyranosyloxy(hydroxyphosphinyl)-L-Leucyl-L-Tryptophan

ID: ALA479579

Cas Number: 36357-77-4

PubChem CID: 445114

Product Number: P113169, Order Now?

Max Phase: Preclinical

Molecular Formula: C23H34N3O10P

Molecular Weight: 543.51

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Phosphoramidon | Phosphramidon | Phosporamidon | phosphoramidon|36357-77-4|Phosphramidon|Phosporamidon|N-ALPHA-L-RHAMNOPYRANOSYLOXY(HYDROXYPHOSPHINYL)-L-LEUCYL-L-TRYPTOPHAN|CHEMBL479579|T3G94E2LB1|CHEBI:45353|Phosphoramidon disodium salt|N-(N-(((6-Deoxy-alpha-L-mannopyranosyl)oxy)hydroxyphosphinyl)-L-leucyl)-L-tryptophan|119942-99-3|L-TRYPTOPHAN,N-[[(6-DEOXY-A-L-MANNOPYRANOSYL)OXY]HYDROXYPHOSPHINYL]-L-LEUCYL-|(hydroxy(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)phosphShow More⌵

Canonical SMILES:  CC(C)C[C@H](NP(=O)(O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

Standard InChI:  InChI=1S/C23H34N3O10P/c1-11(2)8-16(26-37(33,34)36-23-20(29)19(28)18(27)12(3)35-23)21(30)25-17(22(31)32)9-13-10-24-15-7-5-4-6-14(13)15/h4-7,10-12,16-20,23-24,27-29H,8-9H2,1-3H3,(H,25,30)(H,31,32)(H2,26,33,34)/t12-,16-,17-,18-,19+,20+,23-/m0/s1

Standard InChI Key:  ZPHBZEQOLSRPAK-XLCYBJAPSA-N

Molfile:  

     RDKit          2D

 37 39  0  0  1  0  0  0  0  0999 V2000
    0.2125   -4.4625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.5625   -4.9292    0.0000 P   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6000   -4.6167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7500   -5.0875    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1375   -3.9958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4792   -3.6833    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.4208   -6.1792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9125   -5.4000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7208   -5.2417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8708   -3.2167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3708   -4.7750    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.5917   -5.5333    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.2625   -5.8667    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.7708   -5.4292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0583   -3.0583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0708   -5.7083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3417   -4.9292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0250   -6.7417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6125   -6.3333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7167   -5.7417    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.7458   -6.3417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4042   -4.1208    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.6417   -6.1792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.8000   -4.3083    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.9917   -4.4625    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1500   -4.7750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8708   -5.4000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9500   -4.1500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4083   -2.5917    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.2125   -2.2792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0083   -7.5667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1792   -6.8000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4542   -6.7708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9125   -7.5792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9917   -6.6458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7125   -7.9917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4375   -7.5958    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  4  1  0
  3  1  1  0
  1  4  1  1
  5  3  1  0
  6  1  1  0
  7 19  1  0
  8 11  1  0
  9  8  1  0
 10  5  1  0
 11  2  1  0
 12 14  1  0
 13  9  1  0
 14  7  2  0
 15  6  1  0
 16 13  1  6
 17 16  1  0
 18  7  1  0
 19 16  1  0
 20  2  1  0
 21 18  1  0
 22  2  2  0
  8 23  1  6
 24 17  1  0
 25  9  2  0
 26 17  2  0
  3 27  1  6
  5 28  1  6
 10 29  1  1
 15 30  1  6
 31 18  2  0
 32 23  1  0
 33 21  2  0
 34 32  1  0
 35 32  1  0
 36 31  1  0
 37 36  2  0
 15 10  1  0
 21 12  1  0
 37 33  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA479579

   Phosphoramidon

2. Alternative Forms:

   

   ALA479579

   Phosphoramidon disodium salt

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 543.51

Molecular Weight (Monoisotopic): 543.1982

AlogP: 0.23

#Rotatable Bonds: 11

Polar Surface Area: 210.67

Molecular Species: ACID

HBA: 8

HBD: 8

#RO5 Violations: 2

HBA (Lipinski): 13

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 2.48

CX Basic pKa: ┄

CX LogP: 0.16

CX LogD: -5.39

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.18

Np Likeness Score: 0.93

References

1. De Lombaert S, Stamford LB, Blanchard L, Tan J, Hoyer D, Diefenbacher CG, Wei D, Wallace EM, Moskal MA, Savage P, Jeng AY.  (1997)  Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11,  7  (8): [10.1016/S0960-894X(97)00159-5]

2. Elliott RL, Marks N, Berg MJ, Portoghese PS..  (1985)  Synthesis and biological evaluation of phosphonamidate peptide inhibitors of enkephalinase and angiotensin-converting enzyme.,  28  (9): [PMID:2993614] [10.1021/jm00147a015]

3. Chackalamannil S, Chung S, Stamford AW, McKittrick BA, Wang Y, Tsai H, Cleven R, Fawzi A, Czarniecki M.  (1996)  Highly potent and selective inhibitors of endothelin converting enzyme,  6  (11): [10.1016/0960-894X(96)00211-9]

4. Fukami T, Hayama T, Amano Y, Nakamura Y, Arai Y, Matsuyama K, Yano M, Ishikawa K.  (1994)  Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon,  4  (10): [10.1016/S0960-894X(01)80341-3]

5. Lloyd J, Schmidt JB, Hunt JT, Barrish JC, Little DK, Tymiak AA.  (1996)  Solid phase synthesis of phosphinic acid endothelin converting enzyme inhibitors,  6  (12): [10.1016/0960-894X(96)00227-2]

6. Wallace EM, Moliterni JA, Moskal MA, Neubert AD, Marcopulos N, Stamford LB, Trapani AJ, Savage P, Chou M, Jeng AY..  (1998)  Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.,  41  (9): [PMID:9554884] [10.1021/jm970787c]

7. McKittrick BA, Stamford AW, Xiaoyu Weng, Ke Ma, Chackalamannil S, Czarniecki M, Cleven R, Fawzi AB.  (1996)  Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11,  6  (14): [10.1016/0960-894X(96)00297-1]

8. Bohacek RS, McMartin C..  (1992)  Definition and display of steric, hydrophobic, and hydrogen-bonding properties of ligand binding sites in proteins using Lee and Richards accessible surface: validation of a high-resolution graphical tool for drug design.,  35  (10): [PMID:1588550] [10.1021/jm00088a002]

9. Bertenshaw SR, Rogers RS, Stern MK, Norman BH, Moore WM, Jerome GM, Branson LM, McDonald JF, McMahon EG, Palomo MA..  (1993)  Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency.,  36  (1): [PMID:8421284] [10.1021/jm00053a023]

10. Bertenshaw SR, Talley JJ, Rogers RS, Carter JS, Moore WM, Branson LM, Koboldt CM.  (1993)  Thiol and hydroxamic acid containing inhibitors of endothelin converting enzyme,  3  (10): [10.1016/S0960-894X(01)80994-X]

11. Bihovsky R, Levinson BL, Loewi RC, Erhardt PW, Polokoff MA..  (1995)  Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.,  38  (12): [PMID:7783143] [10.1021/jm00012a011]

12. Ksander GM, Diefenbacher CG, Yuan AM, Clark F, Sakane Y, Ghai RD..  (1989)  Enkephalinase inhibitors. 1. 2,4-Dibenzylglutaric acid derivatives.,  32  (12): [PMID:2585440] [10.1021/jm00132a005]

13. Ishchenko AV, Shakhnovich EI..  (2002)  SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.,  45  (13): [PMID:12061879] [10.1021/jm0105833]

14. Lagunin AA, Gomazkov OA, Filimonov DA, Gureeva TA, Dilakyan EA, Kugaevskaya EV, Elisseeva YE, Solovyeva NI, Poroikov VV..  (2003)  Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.,  46  (15): [PMID:12852763] [10.1021/jm021089h]

15. Fink CA, Qiao Y, Berry CJ, Sakane Y, Ghai RD, Trapani AJ..  (1995)  New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.,  38  (26): [PMID:8544178] [10.1021/jm00026a009]

16. De Lombaert S, Blanchard L, Stamford LB, Tan J, Wallace EM, Satoh Y, Fitt J, Hoyer D, Simonsbergen D, Moliterni J, Marcopoulos N, Savage P, Chou M, Trapani AJ, Jeng AY..  (2000)  Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.,  43  (3): [PMID:10669576] [10.1021/jm990507o]

17. De Lombaert S, Erion MD, Tan J, Blanchard L, el-Chehabi L, Ghai RD, Sakane Y, Berry C, Trapani AJ..  (1994)  N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.,  37  (4): [PMID:8120868] [10.1021/jm00030a009]

18. Berger Y, Dehmlow H, Blum-Kaelin D, Kitas EA, Löffler BM, Aebi JD, Juillerat-Jeanneret L..  (2005)  Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.,  48  (2): [PMID:15658862] [10.1021/jm040857x]

19. Mitchell JK, Pitcher D, McArdle BM, Alnefelt T, Duffy S, Avery V, Quinn RJ..  (2007)  Identifying common metalloprotease inhibitors by protein fold types using Fourier transform mass spectrometry.,  17  (23): [PMID:17933532] [10.1016/j.bmcl.2007.09.084]

20. Grice CA, Tays KL, Savall BM, Wei J, Butler CR, Axe FU, Bembenek SD, Fourie AM, Dunford PJ, Lundeen K, Coles F, Xue X, Riley JP, Williams KN, Karlsson L, Edwards JP..  (2008)  Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.,  51  (14): [PMID:18588282] [10.1021/jm701575k]

21. Teramachi F, Koyano T, Kowithayakorn T, Hayashi M, Komiyama K, Ishibashi M..  (2005)  Collagenase inhibitory quinic acid esters from Ipomoea pes-caprae.,  68  (5): [PMID:15921434] [10.1021/np0500631]

22. Olimpieri F, Tambaro S, Fustero S, Lazzari P, Sanchez-Roselló M, Pani L, Volonterio A, Zanda M..  (2009)  Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.,  19  (16): [PMID:19596577] [10.1016/j.bmcl.2009.06.064]

23. Jullien N, Makritis A, Georgiadis D, Beau F, Yiotakis A, Dive V..  (2010)  Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.,  53  (1): [PMID:19899765] [10.1021/jm9010803]

24. Moon HI, Kim TI, Cho HS, Kim EK..  (2010)  Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.,  20  (3): [PMID:20053563] [10.1016/j.bmcl.2009.12.059]

25. Misawa K, Suzuki Y, Takahashi S, Yoshimori A, Takasawa R, Shibuya Y, Tanuma S..  (2011)  Structure-based design of dipeptide derivatives for the human neutral endopeptidase.,  19  (20): [PMID:21937235] [10.1016/j.bmc.2011.08.064]

26. Šlachtová V, Šebela M, Torfs E, Oorts L, Cappoen D, Berka K, Bazgier V, Brulíková L..  (2020)  Novel thiazolidinedione-hydroxamates as inhibitors of Mycobacterium tuberculosis virulence factor Zmp1.,  185  [PMID:31703818] [10.1016/j.ejmech.2019.111812]

27. Sharma U, Cozier GE, Sturrock ED, Acharya KR..  (2020)  Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.,  63  (10): [PMID:32337993] [10.1021/acs.jmedchem.0c00441]

28. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

29. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

30. Wagner S, Sommer R, Hinsberger S, Lu C, Hartmann RW, Empting M, Titz A..  (2016)  Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections.,  59  (13): [PMID:26804741] [10.1021/acs.jmedchem.5b01698]

Source

Source(2):

• Scientific Literature
• SARS-CoV-2 Screening Data 2020-21